Antengene Unveils Groundbreaking R&D Developments at the Second China Biotech Summit

On August 18, 2026, Antengene Corporation Limited, recognized as a forefront global biotech firm, made headlines at the Evercore 2nd China Biotech Summit with remarkable R&D highlights. During a fireside chat session, the company provided updates on its experimental therapies, including the promising ATG-022, an antibody-drug conjugate targeting CLDN18.2, and unveiled its new TriGager™ T-cell engager (TCE) platform.

Clinical Data for ATG-022

Antengene shared significant findings from the Phase II CLINCH study of ATG-022. In the cohort of patients exhibiting moderate to high CLDN18.2 expression, the objective response rate was reported at 42.4% with a remarkable disease control rate of 90.9%. These statistics herald hopes for effective treatment solutions, as patients also exhibited a median overall survival (mOS) of 12.85 months. The 1.8 mg/kg dosage cohort displayed an impressive mOS that had not yet been reached, corroborating the potential for ATG-022 to provide enduring survival advantages across various levels of CLDN18.2 expression.

The treatment showed a favorable safety profile, and despite a slight increase in grade ≥3 treatment-related adverse events (TRAE) from 19.4% to 21.0% over recent months, the incidence remained stable, emphasizing the drug's compatibility with chemotherapy and anti-PD-1 antibody administration in first-line settings.

Antengene is advancing clinical trials of ATG-022 across different lines of gastric cancer treatment, further establishing its commitment to developing effective therapeutics for patients in dire need.

Innovations in T-cell Engager Technologies

In addition to clinical updates, Antengene introduced its proprietary TriGager™ TCE platform and multiple functional modules. This flexible and customizable technology toolbox aims to optimize T-cell engagement, balancing efficacy while maintaining safety. Unlike traditional TCE designs, the TriGager™ platform allows for a more nuanced construction of T-cell engaging molecules, catering to diverse tumor profiles while minimizing off-target toxicity.

The TriGager™ technology boasts mechanisms enabling enhanced specificity through AND-Gate and True AND-Gate logic-gate molecules, requiring dual disease-related antigens to trigger T-cell activity. This design maximizes therapeutic potential while safeguarding against unintended side effects, a critical advancement in the biopharmaceutical industry. Moreover, the inclusion of engineered co-stimulatory elements promises to improve the development capacity and efficacy of these agents.

Introducing ATG-207

A key feature of Antengene’s presentation was the introduction of ATG-207, a globally first-in-class bifunctional fusion protein developed for treating T cell-mediated autoimmune diseases. First revealed at the 2026 European Congress of Rheumatology, ATG-207 highlights Antengene’s commitment to pioneering new treatment modalities in both oncology and immunology fields.

Helping Patients in Need

Antengene Corporation’s resolve to meet pressing medical needs is exemplified in its expansive pipeline featuring investigational candidates like ATG-037, ATG-101, and ATG-125, among others. With a strong focus on innovation and clinical excellence, Antengene aims to reshape treatment paradigms for patients suffering from auto-immune diseases and various cancers.

The company has already gained an impressive 33 investigational new drug (IND) approvals in both the U.S. and Asia, demonstrating a commitment to advancing solutions for unmet medical requirements. Underlining its success, Antengene’s lead product, XPOVIO® (selinexor), has gained approval across several Asia Pacific markets and stands as a testament to the company’s effective strategy in drug development and commercialization.

In conclusion, Antengene’s participation in the Evercore 2nd China Biotech Summit marks yet another significant step in their mission to deliver transformative healthcare solutions. The outcomes shared during the event solidify Antengene’s reputation as a key player in the biotech landscape, inspiring optimism for future advancements in innovative treatments.